Therapies for mobility disability in persons with multiple sclerosis.

Expert Review of Neurotherapeutics
Jessica F BairdRobert W Motl

Abstract

Mobility disability is one of the most widespread and impactful consequences of multiple sclerosis (MS). Disease modifying drugs (DMDs) may delay the progression of disability over time; however, there is minimal evidence supporting the efficacy of DMDs for reversing mobility disability or restoring ambulatory function in persons with MS. Areas covered: This review outlines symptomatic pharmacologic and non-pharmacologic therapeutic approaches that target mobility disability with the goal of restoring and improving walking function. First, the efficacy of dalfampridine, currently the only Food and Drug Administration approved symptomatic pharmacologic agent that improves walking in persons with MS is described. Next, a review of the efficacy of non-pharmacologic therapies for improving walking, including exercise training, physical therapy, and gait training is given. Last, guidance on future research on mobility in MS is provided by emphasizing the importance of combinatory treatment approaches that include multiple intervention modalities, as the best treatment plan likely involves a comprehensive, multidisciplinary approach. Expert commentary: There has been an increased effort to develop symptom-specific treatments in MS th...Continue Reading

References

Feb 13, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·C M WilesA Morgan
May 4, 2001·Brain : a Journal of Neurology·J HobartA Thompson
May 24, 2001·Current Opinion in Neurology·C Bjartmar, B D Trapp
Sep 16, 2004·QJM : Monthly Journal of the Association of Physicians·L HemmettN Russell
Oct 1, 2004·Brain : a Journal of Neurology·Katrin MorgenLeonardo G Cohen
Sep 20, 2005·Lancet Neurology·Jürg Kesselring, Serafin Beer
Aug 26, 2006·Nature Clinical Practice. Neurology·Bernhard HemmerHans-Peter Hartung
Oct 19, 2007·Multiple Sclerosis : Clinical and Laboratory Research·S BeerJ Kesselring
May 29, 2008·Multiple Sclerosis : Clinical and Laboratory Research·C HeesenS M Gold
Jun 19, 2008·Annual Review of Neuroscience·Bruce D Trapp, Klaus-Armin Nave
Aug 2, 2008·Neurology·A D GoodmanUNKNOWN Fampridine MS-F202 Study Group
Oct 25, 2008·Neurorehabilitation and Neural Repair·Erin M Snook, Robert W Motl
Oct 31, 2008·Neurorehabilitation and Neural Repair·Albert C Lo, Elizabeth W Triche
Mar 3, 2009·Lancet·Andrew D GoodmanUNKNOWN Fampridine MS-F203 Investigators
Aug 12, 2009·Multiple Sclerosis : Clinical and Laboratory Research·F HamiltonJ J Evans
Mar 11, 2010·American Journal of Physical Medicine & Rehabilitation·Burcu Duyur CaktUfuk Ergün
Sep 28, 2010·Exercise and Sport Sciences Reviews·Robert W Motl
Oct 27, 2010·Annals of Neurology·Andrew D GoodmanUNKNOWN MSF204 Investigators
Dec 22, 2010·Neuropsychiatric Disease and Treatment·Robert W MotlRalph H B Benedict
Feb 2, 2011·Proceedings of the National Academy of Sciences of the United States of America·Kirk I EricksonArthur F Kramer
Apr 14, 2011·Journal of the International Neuropsychological Society : JINS·Ralph H B BenedictBianca Weinstock-Guttman
May 20, 2011·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Roee HoltzerJoe Verghese
Dec 8, 2011·Multiple Sclerosis : Clinical and Laboratory Research·Isabella SchwartzZeev Meiner
Mar 26, 2013·Journal of the Neurological Sciences·Brian M SandroffRobert W Motl
Apr 17, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Yvonne C LearmonthRobert W Motl
Apr 20, 2013·Physical Medicine and Rehabilitation Clinics of North America·Robert W Motl
Oct 26, 2013·Multiple Sclerosis : Clinical and Laboratory Research·S BrikenC Heesen
Jan 22, 2014·Journal of Internal Medicine·A H Cross, R T Naismith
Feb 4, 2014·Mayo Clinic Proceedings·Dean M Wingerchuk, Jonathan L Carter
Feb 5, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Ulrik Dalgas, Egon Stenager
Mar 4, 2014·Therapeutic Advances in Neurological Disorders·Henrik Boye JensenEgon Stenager
Jun 2, 2014·Journal of the Neurological Sciences·Lara A PiluttiAmy E Latimer-Cheung
Jun 3, 2014·Neuroscience·D Zeller, J Classen
Aug 27, 2014·Annals of the New York Academy of Sciences·Andrew R BlightRon Cohen
Sep 3, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Carmela LeonePeter Feys
Oct 23, 2014·International Journal of MS Care·Andrew D GoodmanAndrew R Blight

❮ Previous
Next ❯

Citations

May 14, 2019·Neurorehabilitation and Neural Repair·Lousin MoumdjianPeter Feys
Oct 4, 2019·Neurodegenerative Disease Management·Elizbeth Morghen SikesRobert W Motl
Apr 19, 2020·Current Opinion in Neurology·Diego CentonzePeter Feys
Jul 31, 2020·Expert Review of Neurotherapeutics·Bernardita SolerPeter Feys
Jul 16, 2020·Expert Review of Neurotherapeutics·Robert W Motl, Brian M Sandroff
Aug 9, 2020·Neurodegenerative Disease Management·Eva Costa Arpín
May 1, 2021·International Journal of Environmental Research and Public Health·Jessica F Baird, Robert W Motl
Apr 18, 2021·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Ilaria CarpinellaDavide Cattaneo
Mar 1, 2021·Reviews in the Neurosciences·Athina-Maria AloizouEfthimios Dardiotis
Dec 12, 2021·Disability and Rehabilitation. Assistive Technology·Stephanie L SilveiraRobert W Motl

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Neurology, Neurosurgery, and Psychiatry
Emilio PortaccioMS Study Group of the Italian Neurological Society
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Kate Traynor
© 2022 Meta ULC. All rights reserved